Skip to main content
ALLO $0.84 +1.41%
ALLO logo
ALLO · Allogene Therapeutics, Inc.
Track ALLO — free
$0.84 +0.01 (+1.41%) At close · Nov 13 Play latest call Q2 2026 earnings call transcript
Market Cap
$290.58M
Shares
346.47M
Volume · Nov 13 11.66M Avg daily vol (3M) 7.37M
All webcasts

Earnings call · FY2026 Q3

Allogene Therapeutics, Inc. (ALLO) Q3 2026 Earnings Call

Concluded Nov 5, 2026
Nov 5, 2026
Period
FY2026 Q3
Runtime
—
Sources
2 artifacts
Revenue $0
Diluted EPS -$0.15
Net income -$50.37M
Open full screen 8-K 10-Q

Executive readout · one minute

What the filings say

10-Q report · filed Nov 6, 2026
Allogene Therapeutics reported ALPHA3 interim results showing MRD negativity in 58.3% (7/12) of cema-cel patients versus 16.7% (2/12) under observation, with no treatment-related serious adverse events reported in the cema-cel arm.

The audio replay and transcript follow the call.

Research coverage

2 live sources

Open each available source without leaving this research workspace.

Research materials

Open the source you need; every reader stays inside this workspace.

Full-screen source Call document